公开(公告)号：EP1469071A4

公开(公告)日：2006-02-15

申请号：EP03703025

申请日：2003-01-22

申请人： ASTELLAS PHARMA INC

发明人： ENDOH HIDEKI ,  NAKANO RYOSUKE ,  KUROSAKI EIJI ,  KATO MIYUKI ,  YOKOTA HIROYUKI ,  INABE KAZUNORI

IPC分类号： A61P3/10 ,  C12N1/19 ,  C12N1/21 ,  C12N15/10 ,  C12N15/12 ,  C12Q1/68 ,  G01N33/566 ,  C07K14/705 ,  C07K16/18 ,  C12N15/62 ,  C12N15/81 ,  C12Q1/66

CPC分类号： G01N33/566 ,  C12N15/1055 ,  C12Q1/6897 ,  G01N2333/70567

摘要： It is intended to disclose a method of screening a protein which ligand-dependently interacts with PPAR and is highly useful as a tool for screening a drug improving insulin resistance. Using this method, a main effect ligand-dependent PPAR-binding molecule ECHLP, a main effect ligand-selective PPARgamma acting factor FLJ13111 and a side effect ligand-dependent PPAR-binding molecule AOP2 are obtained. It is also intended to disclose a screening system for a drug improving insulin resistance selectively exerting the main effect without causing any side effect which is constructed by using PPAR-interacting ECHLP, PPAR-interacting FLJ13111 and PPAR-interacting AOP2. It is furthermore intended to disclose a process for producing medicinal compositions for improving insulin resistance containing, as the active ingredient, a PPAR main effect promoter, a PPAR main effect-specific agonist, a PPAR-interacting ECHLP inhibitor promoting the main effect of PPAR, a substance regulating the side effect of PPARgamma, a PPAR-interacting AOP2 inhibitor regulating the side effect of PPARgamma, a PPAR-interacting FLJ1311 activator promoting the main effect of PPAR or an FLJ13111 expression accelerator which can be obtained by the above screening method.

公开(公告)号：EP1541551A4

公开(公告)日：2007-01-24

申请号：EP03741499

申请日：2003-07-18

申请人： ASTELLAS PHARMA INC

发明人： HAYAKAWA MASAHIKO ,  NEGORO KENJI ,  MIYAMOTO SATOSHI ,  SUZUKI TAKAYUKI ,  MARUYAMA TATSUYA ,  NAKANO RYOSUKE

IPC分类号： C07D207/16 ,  A61K31/4025 ,  A61K31/4155 ,  A61K31/439 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/541 ,  A61P3/10 ,  A61P43/00 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D451/04 ,  C07D471/06

CPC分类号： C07D401/12 ,  C07D207/16 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D451/04

摘要： It is intended to provide a compound having an excellent effect of inhibiting dipeptidylpeptidase IV, and an excellent remedy for insulin-dependent diabetes (type 1 diabetes), in particular, insulin-independent diabetes (type 2 diabetes), insulin resistance disease and obesity based on the above effect.

摘要翻译： 本发明意图提供抑制二肽基肽酶IV的优异效果的化合物以及胰岛素依赖性糖尿病（1型糖尿病），特别是胰岛素非依赖性糖尿病（2型糖尿病），胰岛素抵抗性疾病和基于肥胖症的优异的治疗剂 对上述影响。